Holen Sie sich die Stockscreener-App
17.84
3.04%
-0.56
Schlusskurs vom Vortag:
$18.40
Offen:
$18.32
24-Stunden-Volumen:
1.03M
Relative Volume:
0.55
Marktkapitalisierung:
$2.53B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.61M
KGV:
-55.15
EPS:
-0.3235
Netto-Cashflow:
$-45.40M
1W Leistung:
-0.50%
1M Leistung:
+33.13%
6M Leistung:
+59.57%
1J Leistung:
+178.32%
1-Tages-Spanne:
$17.52
$18.33
1-Wochen-Bereich:
$17.52
$20.15
52-Wochen-Spanne:
$6.245
$20.15
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Firmenname
Trevi Therapeutics Inc
Sektor
Branche
Telefon
203-304-2499
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
17.84 | 2.53B | 0 | -45.61M | -45.40M | -0.3235 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Leerink Partners | Outperform |
| 2025-08-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-07-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Bestätigt | Needham | Buy |
| 2025-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-30 | Eingeleitet | Raymond James | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-12 | Eingeleitet | B. Riley Securities | Buy |
| 2022-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-06-03 | Eingeleitet | Needham | Buy |
| 2019-06-03 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | Stifel | Buy |
Alle ansehen
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
Trevi Therapeutics Targets Refractory Chronic Cough With Fresh Phase 2 Trial - TipRanks
SG Americas Securities LLC Decreases Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
TRVi stock stays tied to Trevi Therapeutics' clinical outlook - ad-hoc-news.de
Price to sales forward of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
Price to book forward of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
Price to earnings forward of Trevi Therapeutics, Inc. – BOATS:TRVI - TradingView
Trevi Therapeutics stock hits all-time high at 19.33 USD By Investing.com - Investing.com South Africa
Trevi Therapeutics stock hits all-time high at 19.33 USD - Investing.com
$Trevi Therapeutics (TRVI.US)$ keep squeezing baby - Moomoo
Should Trevi’s Multi‑Index Russell Exit Reshape How Haduvio Drives the Trevi Therapeutics (TRVI) Story? - simplywall.st
Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell Microcap Index - marketscreener.com
Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell 3000E Index - marketscreener.com
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $18 to $23 - Moomoo
Trevi Therapeutics stock hits all-time high at 18.17 USD By Investing.com - Investing.com Australia
Trevi Therapeutics stock hits all-time high at 18.17 USD - Investing.com
Trevi Therapeutics, Inc. Actuals & Estimates (NASDAQ:TRVI) - TradingView
TRVI Forecast — Price Target — Prediction for 2027 - TradingView
Trevi Therapeutics Inc (TRVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
$Trevi Therapeutics (TRVI.US)$ finally you are getting squeezed - Moomoo
Trevi Therapeutics Inc (TRVI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Trevi Therapeutics Inc (TRVI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Trevi Therapeutics Inc (TRVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Trevi Therapeutics Inc (TRVI) Institutional Confidence - TradingKey
Trevi Therapeutics Inc (TRVI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Trevi Therapeutics Inc (TRVI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Trevi Therapeutics stock hits all-time high at 16.13 USD By Investing.com - Investing.com Nigeria
Trevi Therapeutics Inc (TRVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Trevi Therapeutics Inc (TRVI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Trevi Therapeutics Announces Upcoming June and July Event Schedule - GlobeNewswire
Trevi Therapeutics stock hits all-time high at 16.13 USD - Investing.com
Trevi Therapeutics Slides As Hot Biotech Rally Cools - TipRanks
Trevi Therapeutics (TRVI) Surges 5.05% as Momentum Builds Near ResistanceBox Spread - dars.gov.et
128,306,056 Common Stock of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
Certain Stock Options of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
Certain Warrants of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
TRVI Q1 2026 Earnings: Clinical Progress Drives Stock Gains Despite EPS MissEarnings Call Q&A - newsline.com
Trevi Therapeutics Shareholders Approve Stock and Governance Changes - The Globe and Mail
Trevi Therapeutics (TRVI) director receives 35,000-share stock option grant - Stock Titan
Trevi Therapeutics (TRVI) doubles authorized stock, adds 8,000,000-plan shares - Stock Titan
[Form 4] Trevi Therapeutics, Inc. Insider Trading Activity - Stock Titan
Trevi Therapeutics (TRVI) director receives 35K nonstatutory option grant - Stock Titan
Director at Trevi Therapeutics (NASDAQ: TRVI) awarded 35,000 stock options - Stock Titan
Director at Trevi Therapeutics (TRVI) receives 35,000 stock options award - Stock Titan
Trevi Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. - AOL.com
TRVI: All proposals passed, including share increase and director election, with no shareholder questions - TradingView
Pivotal bioVenture Partners Increases Trevi Therapeutics Holdings by 296,944 Shares in Q1 2026News and Statistics - IndexBox
Trevi Therapeutics stock hits 52-week low at 13.68 USD By Investing.com - Investing.com Canada
Trevi Therapeutics stock hits 52-week low at 13.68 USD - Investing.com
Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):